Small Molecules
27 October 2016
BioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) Nonclinical Results in Zika Virus Infection at IDWeek 201626 October 2016
LYNPARZA (olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit26 October 2016
Aeterna Zentaris Completes Patient Recruitment for Confirmatory Phase 3 Trial of Macrilen25 October 2016
Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 145025 October 2016
Lexicon Reports Positive Top-Line Results In Phase 2 Dose-Ranging Study For Sotagliflozin In Patients With Type 1 Diabetes24 October 2016
Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections21 October 2016
Spinal Muscular Atrophy Program Advances into Phase 2 Clinical Studies in SMA Patients with RG791621 October 2016
Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder20 October 2016
Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP20 October 2016
Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis (NASH)20 October 2016
Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports